Clene Inc. (CLNN)

NASDAQ: CLNN · IEX Real-Time Price · USD
0.528
+0.003 (0.57%)
At close: Sep 27, 2023, 4:00 PM
0.550
+0.022 (4.17%)
After-hours: Sep 27, 2023, 7:53 PM EDT
0.57%
Market Cap 67.80M
Revenue (ttm) 784,000
Net Income (ttm) -48.94M
Shares Out 128.41M
EPS (ttm) -0.61
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 533,547
Open 0.520
Previous Close 0.525
Day's Range 0.515 - 0.550
52-Week Range 0.410 - 3.230
Beta 0.32
Analysts Strong Buy
Price Target 7.00 (+1,225.76%)
Earnings Date Nov 6, 2023

About CLNN

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 75
Stock Exchange NASDAQ
Ticker Symbol CLNN
Full Company Profile

Financial Performance

In 2022, Clene's revenue was $473,000, a decrease of -34.58% compared to the previous year's $723,000. Losses were -$29.92 million, 207.2% more than in 2021.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for CLNN stock is "Strong Buy." The 12-month stock price forecast is $7.0, which is an increase of 1,225.76% from the latest price.

Price Target
$7.0
(1,225.76% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference

SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage bioph...

2 days ago - GlobeNewsWire

Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls

SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) through its wholly owned subsidiary Clene Nanomedicine, Inc. (collectively “Clene”), today announced long-term follow-up da...

3 days ago - GlobeNewsWire

Clene to Present at Upcoming September Conferences

SALT LAKE CITY, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopha...

4 weeks ago - GlobeNewsWire

Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up

SALT LAKE CITY, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) through its wholly owned subsidiary Clene Nanomedicine Inc., today announced the 24-month long-term data cut from the Phase ...

4 weeks ago - GlobeNewsWire

Clene Reports Second Quarter 2023 Financial Results and Operating Highlights

SALT LAKE CITY, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopha...

6 weeks ago - GlobeNewsWire

Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference

SALT LAKE CITY, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmace...

2 months ago - GlobeNewsWire

Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET's eClinicalMedicine

SALT LAKE CITY, June 26, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmac...

3 months ago - GlobeNewsWire

Clene Welcomes New Shareholder Base and Announces Closing of Underwritten Public Offering of $40 Million

SALT LAKE CITY, June 21, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharma...

3 months ago - GlobeNewsWire

Clene Announces Pricing of $40 Million Public Offering

SALT LAKE CITY, June 16, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceu...

3 months ago - GlobeNewsWire

Clene Announces Launch of Proposed Public Offering

SALT LAKE CITY, June 15, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceu...

3 months ago - GlobeNewsWire

Clene's CNM-Au8® Shows Statistically Significant Difference in Plasma Neurofilament Light (NfL) levels in the HEALEY ALS Platform Trial

SALT LAKE CITY, June 15, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharma...

3 months ago - GlobeNewsWire

Clene to Participate in the Maxim Group Virtual Healthcare Conference

SALT LAKE CITY, June 15, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmace...

3 months ago - GlobeNewsWire

Clene Reports First Quarter 2023 Financial Results and Recent Operating Highlights

SALT LAKE CITY, May 12, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceu...

4 months ago - GlobeNewsWire

ALS and MS Clinical Data from Clene's CNM-Au8® Featured in Multiple Presentations at the 2023 American Academy of Neurology Annual Meeting

SALT LAKE CITY, April 25, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharma...

5 months ago - GlobeNewsWire

Clene Announces the Plenary Presentations of MS and ALS Data Supporting the Efficacy and Safety of CNM-Au8® at the 2023 American Academy of Neurology Annual Meeting

SALT LAKE CITY, April 11, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharma...

6 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Clene Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

NEW YORK , March 20, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty clai...

6 months ago - PRNewsWire

Clene Appoints Neurology Expert to Executive Team

SALT LAKE CITY, March 16, 2023 (GLOBE NEWSWIRE) -- Clene, Inc. (Nasdaq: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmace...

6 months ago - GlobeNewsWire

Clene Reports Full Year 2022 Financial Results and Recent Operating Highlights

SALT LAKE CITY, March 13, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmac...

7 months ago - GlobeNewsWire

CNM-Au8® Associated With Delayed Time to Key Clinical Progression Events at Six Months Supporting a Survival Benefit in the Healey ALS Platform Trial

Clene will host a live audio webcast at 7:30 a.m. EST today to review these new clinical results.

7 months ago - GlobeNewsWire

Clene to Announce New CNM-Au8® Data From the Healey ALS Platform Trial

Webcast set for 7:30 a.m. ET on March 9 Webcast set for 7:30 a.m. ET on March 9

7 months ago - GlobeNewsWire

Clene Nanomedicine to Participate in Roth's 35th Annual Healthcare Conference and Renmark Virtual Non-Deal Roadshow Series

SALT LAKE CITY, March 07, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmac...

7 months ago - GlobeNewsWire

Clene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8® Treatment Improved Brain Neuronal Structural Integrity

SALT LAKE CITY, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmace...

8 months ago - GlobeNewsWire

Clene Nanomedicine Announces Participation in Renmark Virtual Non-Deal Roadshow Series on January 18 and January 23

SALT LAKE CITY, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmace...

9 months ago - GlobeNewsWire

Clene Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg

SALT LAKE CITY, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmace...

9 months ago - GlobeNewsWire

Clene Announces Closing of $5 Million Debt Facility from the State of Maryland

Funding Demonstrates Importance of Working with Private Sector to Improve Lives of Marylanders, says Governor Hogan Funding Demonstrates Importance of Working with Private Sector to Improve Lives of M...

10 months ago - GlobeNewsWire